ARS Pharmaceuticals, Inc.
Moat Score — ARS Pharmaceuticals, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Seven-plus FDA-approved CNS products protected by formulation and method-of-use patents, including Qelbree (first novel nonstimulant ADHD drug since 2011) and ZURZUVAE (first oral postpartum depression treatment, acquired via Sage Therapeutics), give Supernus durable but non-blockbuster IP spread across several niches rather than one dominant patent estate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Supernus owns no manufacturing and relies entirely on third-party contract manufacturers across North America, Europe, and Asia, so it has no structural cost advantage over branded-pharma peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Branded, patent-protected status in niche indications (nonstimulant ADHD, oral PPD) supports premium pricing versus generics, though legacy epilepsy products (Trokendi XR, Oxtellar XR) are already seeing generic-driven price and volume erosion. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a traditional specialty pharmaceutical seller, Supernus's products carry no network effect — a prescriber's or patient's value from a drug does not increase as more people use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Psychiatrists and neurologists are often reluctant to switch a stabilized patient off a working CNS regimen, giving modest stickiness, but this is weaker than in categories with complex dosing titration or implanted devices. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Supernus's niche indications (nonstimulant ADHD, PD 'OFF' episodes, PPD) are not large enough markets to deter well-funded entrants, and the Sage acquisition was explicitly pursued to add scale rather than reflecting scale Supernus already had. |